Global Duchenne Muscular Dystrophy Market by End User (Clinics, Hospitals, Home care Settings), by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs (Pain Management Drugs, Corticosteroids, Non-steroidal Anti-inflammatory drugs NSAIDs), by Application (Mutation Suppression, Exon Skipping Approach) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Duchenne Muscular Dystrophy Market research report which is segmented by End User (Clinics, Hospitals, Home care Settings), by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs (Pain Management Drugs, Corticosteroids, Non-steroidal Anti-inflammatory drugs NSAIDs), by Application (Mutation Suppression, Exon Skipping Approach), By Players/Companies Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc., Acceleron Pharma Inc., Nippon Shokubai Co. Ltd, Pfizer Inc., PTC Therapeutics Inc., Lexicon Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Tahio Pharmaceutical Co. Ltd, Eli Lilly and Company”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Duchenne Muscular Dystrophy Market Research Report |
| By End User | Clinics, Hospitals, Home care Settings |
| By Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs | Pain Management Drugs, Corticosteroids, Non-steroidal Anti-inflammatory drugs NSAIDs |
| By Application | Mutation Suppression, Exon Skipping Approach |
| By Companies | Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc., Acceleron Pharma Inc., Nippon Shokubai Co. Ltd, Pfizer Inc., PTC Therapeutics Inc., Lexicon Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Tahio Pharmaceutical Co. Ltd, Eli Lilly and Company |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 249 |
| Number of Tables & Figures | 175 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Duchenne Muscular Dystrophy Market Report Segments:
The market is segmented by End User (Clinics, Hospitals, Home care Settings), by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs (Pain Management Drugs, Corticosteroids, Non-steroidal Anti-inflammatory drugs NSAIDs), by Application (Mutation Suppression, Exon Skipping Approach).
Duchenne Muscular Dystrophy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Duchenne Muscular Dystrophy Market
Overview of the regional outlook of the Duchenne Muscular Dystrophy Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Duchenne Muscular Dystrophy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Duchenne Muscular Dystrophy Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Clinics
2. Hospitals
3. Home care Settings
7. By Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs:1. Pain Management Drugs
2. Corticosteroids
3. Non-steroidal Anti-inflammatory drugs NSAIDs
8. By Application:1. Mutation Suppression
2. Exon Skipping Approach
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Duchenne Muscular Dystrophy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Duchenne Muscular Dystrophy Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Duchenne Muscular Dystrophy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Duchenne Muscular Dystrophy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Duchenne Muscular Dystrophy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Duchenne Muscular Dystrophy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Duchenne Muscular Dystrophy Market Size & Forecast, 2018-2028
4.5.1 Duchenne Muscular Dystrophy Market Size and Y-o-Y Growth
4.5.2 Duchenne Muscular Dystrophy Market Absolute $ Opportunity
Chapter 5 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by End User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End User
5.1.2 Basis Point Share (BPS) Analysis by End User
5.1.3 Absolute $ Opportunity Assessment by End User
5.2 Duchenne Muscular Dystrophy Market Size Forecast by End User
5.2.1 Clinics
5.2.2 Hospitals
5.2.3 Home care Settings
5.3 Market Attractiveness Analysis by End User
Chapter 6 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1.2 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1.3 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.2 Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.2.1 Pain Management Drugs
6.2.2 Corticosteroids
6.2.3 Non-steroidal Anti-inflammatory drugs NSAIDs
6.3 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
Chapter 7 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Application
7.1.2 Basis Point Share (BPS) Analysis by Application
7.1.3 Absolute $ Opportunity Assessment by Application
7.2 Duchenne Muscular Dystrophy Market Size Forecast by Application
7.2.1 Mutation Suppression
7.2.2 Exon Skipping Approach
7.3 Market Attractiveness Analysis by Application
Chapter 8 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Duchenne Muscular Dystrophy Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Duchenne Muscular Dystrophy Analysis and Forecast
10.1 Introduction
10.2 North America Duchenne Muscular Dystrophy Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Duchenne Muscular Dystrophy Market Size Forecast by End User
10.6.1 Clinics
10.6.2 Hospitals
10.6.3 Home care Settings
10.7 Basis Point Share (BPS) Analysis by End User
10.8 Absolute $ Opportunity Assessment by End User
10.9 Market Attractiveness Analysis by End User
10.10 North America Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.10.1 Pain Management Drugs
10.10.2 Corticosteroids
10.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
10.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.14 North America Duchenne Muscular Dystrophy Market Size Forecast by Application
10.14.1 Mutation Suppression
10.14.2 Exon Skipping Approach
10.15 Basis Point Share (BPS) Analysis by Application
10.16 Absolute $ Opportunity Assessment by Application
10.17 Market Attractiveness Analysis by Application
Chapter 11 Europe Duchenne Muscular Dystrophy Analysis and Forecast
11.1 Introduction
11.2 Europe Duchenne Muscular Dystrophy Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Duchenne Muscular Dystrophy Market Size Forecast by End User
11.6.1 Clinics
11.6.2 Hospitals
11.6.3 Home care Settings
11.7 Basis Point Share (BPS) Analysis by End User
11.8 Absolute $ Opportunity Assessment by End User
11.9 Market Attractiveness Analysis by End User
11.10 Europe Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.10.1 Pain Management Drugs
11.10.2 Corticosteroids
11.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
11.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.14 Europe Duchenne Muscular Dystrophy Market Size Forecast by Application
11.14.1 Mutation Suppression
11.14.2 Exon Skipping Approach
11.15 Basis Point Share (BPS) Analysis by Application
11.16 Absolute $ Opportunity Assessment by Application
11.17 Market Attractiveness Analysis by Application
Chapter 12 Asia Pacific Duchenne Muscular Dystrophy Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by End User
12.6.1 Clinics
12.6.2 Hospitals
12.6.3 Home care Settings
12.7 Basis Point Share (BPS) Analysis by End User
12.8 Absolute $ Opportunity Assessment by End User
12.9 Market Attractiveness Analysis by End User
12.10 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.10.1 Pain Management Drugs
12.10.2 Corticosteroids
12.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
12.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.14 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Application
12.14.1 Mutation Suppression
12.14.2 Exon Skipping Approach
12.15 Basis Point Share (BPS) Analysis by Application
12.16 Absolute $ Opportunity Assessment by Application
12.17 Market Attractiveness Analysis by Application
Chapter 13 Latin America Duchenne Muscular Dystrophy Analysis and Forecast
13.1 Introduction
13.2 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Duchenne Muscular Dystrophy Market Size Forecast by End User
13.6.1 Clinics
13.6.2 Hospitals
13.6.3 Home care Settings
13.7 Basis Point Share (BPS) Analysis by End User
13.8 Absolute $ Opportunity Assessment by End User
13.9 Market Attractiveness Analysis by End User
13.10 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.10.1 Pain Management Drugs
13.10.2 Corticosteroids
13.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
13.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.14 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Application
13.14.1 Mutation Suppression
13.14.2 Exon Skipping Approach
13.15 Basis Point Share (BPS) Analysis by Application
13.16 Absolute $ Opportunity Assessment by Application
13.17 Market Attractiveness Analysis by Application
Chapter 14 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by End User
14.6.1 Clinics
14.6.2 Hospitals
14.6.3 Home care Settings
14.7 Basis Point Share (BPS) Analysis by End User
14.8 Absolute $ Opportunity Assessment by End User
14.9 Market Attractiveness Analysis by End User
14.10 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.10.1 Pain Management Drugs
14.10.2 Corticosteroids
14.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
14.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.14 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Application
14.14.1 Mutation Suppression
14.14.2 Exon Skipping Approach
14.15 Basis Point Share (BPS) Analysis by Application
14.16 Absolute $ Opportunity Assessment by Application
14.17 Market Attractiveness Analysis by Application
Chapter 15 Competition Landscape
15.1 Duchenne Muscular Dystrophy Market: Competitive Dashboard
15.2 Global Duchenne Muscular Dystrophy Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Bristol-Myers Squibb Company
15.3.2 Janssen Pharmaceuticals Inc.
15.3.3 Acceleron Pharma Inc.
15.3.4 Nippon Shokubai Co. Ltd
15.3.5 Pfizer Inc.
15.3.6 PTC Therapeutics Inc.
15.3.7 Lexicon Pharmaceuticals Inc.
15.3.8 BioMarin Pharmaceutical Inc.
15.3.9 Tahio Pharmaceutical Co. Ltd
15.3.10 Eli Lilly and Company
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Duchenne Muscular Dystrophy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Duchenne Muscular Dystrophy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Duchenne Muscular Dystrophy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Duchenne Muscular Dystrophy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Duchenne Muscular Dystrophy Market Size & Forecast, 2018-2028
4.5.1 Duchenne Muscular Dystrophy Market Size and Y-o-Y Growth
4.5.2 Duchenne Muscular Dystrophy Market Absolute $ Opportunity
Chapter 5 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by End User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End User
5.1.2 Basis Point Share (BPS) Analysis by End User
5.1.3 Absolute $ Opportunity Assessment by End User
5.2 Duchenne Muscular Dystrophy Market Size Forecast by End User
5.2.1 Clinics
5.2.2 Hospitals
5.2.3 Home care Settings
5.3 Market Attractiveness Analysis by End User
Chapter 6 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1.2 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.1.3 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.2 Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
6.2.1 Pain Management Drugs
6.2.2 Corticosteroids
6.2.3 Non-steroidal Anti-inflammatory drugs NSAIDs
6.3 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
Chapter 7 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Application
7.1.2 Basis Point Share (BPS) Analysis by Application
7.1.3 Absolute $ Opportunity Assessment by Application
7.2 Duchenne Muscular Dystrophy Market Size Forecast by Application
7.2.1 Mutation Suppression
7.2.2 Exon Skipping Approach
7.3 Market Attractiveness Analysis by Application
Chapter 8 Global Duchenne Muscular Dystrophy Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Duchenne Muscular Dystrophy Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Duchenne Muscular Dystrophy Analysis and Forecast
10.1 Introduction
10.2 North America Duchenne Muscular Dystrophy Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Duchenne Muscular Dystrophy Market Size Forecast by End User
10.6.1 Clinics
10.6.2 Hospitals
10.6.3 Home care Settings
10.7 Basis Point Share (BPS) Analysis by End User
10.8 Absolute $ Opportunity Assessment by End User
10.9 Market Attractiveness Analysis by End User
10.10 North America Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.10.1 Pain Management Drugs
10.10.2 Corticosteroids
10.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
10.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
10.14 North America Duchenne Muscular Dystrophy Market Size Forecast by Application
10.14.1 Mutation Suppression
10.14.2 Exon Skipping Approach
10.15 Basis Point Share (BPS) Analysis by Application
10.16 Absolute $ Opportunity Assessment by Application
10.17 Market Attractiveness Analysis by Application
Chapter 11 Europe Duchenne Muscular Dystrophy Analysis and Forecast
11.1 Introduction
11.2 Europe Duchenne Muscular Dystrophy Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Duchenne Muscular Dystrophy Market Size Forecast by End User
11.6.1 Clinics
11.6.2 Hospitals
11.6.3 Home care Settings
11.7 Basis Point Share (BPS) Analysis by End User
11.8 Absolute $ Opportunity Assessment by End User
11.9 Market Attractiveness Analysis by End User
11.10 Europe Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.10.1 Pain Management Drugs
11.10.2 Corticosteroids
11.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
11.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
11.14 Europe Duchenne Muscular Dystrophy Market Size Forecast by Application
11.14.1 Mutation Suppression
11.14.2 Exon Skipping Approach
11.15 Basis Point Share (BPS) Analysis by Application
11.16 Absolute $ Opportunity Assessment by Application
11.17 Market Attractiveness Analysis by Application
Chapter 12 Asia Pacific Duchenne Muscular Dystrophy Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by End User
12.6.1 Clinics
12.6.2 Hospitals
12.6.3 Home care Settings
12.7 Basis Point Share (BPS) Analysis by End User
12.8 Absolute $ Opportunity Assessment by End User
12.9 Market Attractiveness Analysis by End User
12.10 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.10.1 Pain Management Drugs
12.10.2 Corticosteroids
12.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
12.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
12.14 Asia Pacific Duchenne Muscular Dystrophy Market Size Forecast by Application
12.14.1 Mutation Suppression
12.14.2 Exon Skipping Approach
12.15 Basis Point Share (BPS) Analysis by Application
12.16 Absolute $ Opportunity Assessment by Application
12.17 Market Attractiveness Analysis by Application
Chapter 13 Latin America Duchenne Muscular Dystrophy Analysis and Forecast
13.1 Introduction
13.2 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Duchenne Muscular Dystrophy Market Size Forecast by End User
13.6.1 Clinics
13.6.2 Hospitals
13.6.3 Home care Settings
13.7 Basis Point Share (BPS) Analysis by End User
13.8 Absolute $ Opportunity Assessment by End User
13.9 Market Attractiveness Analysis by End User
13.10 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.10.1 Pain Management Drugs
13.10.2 Corticosteroids
13.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
13.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
13.14 Latin America Duchenne Muscular Dystrophy Market Size Forecast by Application
13.14.1 Mutation Suppression
13.14.2 Exon Skipping Approach
13.15 Basis Point Share (BPS) Analysis by Application
13.16 Absolute $ Opportunity Assessment by Application
13.17 Market Attractiveness Analysis by Application
Chapter 14 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by End User
14.6.1 Clinics
14.6.2 Hospitals
14.6.3 Home care Settings
14.7 Basis Point Share (BPS) Analysis by End User
14.8 Absolute $ Opportunity Assessment by End User
14.9 Market Attractiveness Analysis by End User
14.10 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.10.1 Pain Management Drugs
14.10.2 Corticosteroids
14.10.3 Non-steroidal Anti-inflammatory drugs NSAIDs
14.11 Basis Point Share (BPS) Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.12 Absolute $ Opportunity Assessment by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.13 Market Attractiveness Analysis by Product Type (Pain Management DrugsCorticosteroids Non-steroidal Anti-inflammatory drugs
14.14 Middle East & Africa (MEA) Duchenne Muscular Dystrophy Market Size Forecast by Application
14.14.1 Mutation Suppression
14.14.2 Exon Skipping Approach
14.15 Basis Point Share (BPS) Analysis by Application
14.16 Absolute $ Opportunity Assessment by Application
14.17 Market Attractiveness Analysis by Application
Chapter 15 Competition Landscape
15.1 Duchenne Muscular Dystrophy Market: Competitive Dashboard
15.2 Global Duchenne Muscular Dystrophy Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Bristol-Myers Squibb Company
15.3.2 Janssen Pharmaceuticals Inc.
15.3.3 Acceleron Pharma Inc.
15.3.4 Nippon Shokubai Co. Ltd
15.3.5 Pfizer Inc.
15.3.6 PTC Therapeutics Inc.
15.3.7 Lexicon Pharmaceuticals Inc.
15.3.8 BioMarin Pharmaceutical Inc.
15.3.9 Tahio Pharmaceutical Co. Ltd
15.3.10 Eli Lilly and Company
Segments Covered in the Report
The global Duchenne Muscular Dystrophy market has been segmented based on
By End User
The global Duchenne Muscular Dystrophy market has been segmented based on
By End User
- Clinics
- Hospitals
- Home care Settings
- Pain Management Drugs
- Corticosteroids
- Non-steroidal Anti-inflammatory drugs NSAIDs
- Mutation Suppression
- Exon Skipping Approach
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals Inc.
- Acceleron Pharma Inc.
- Nippon Shokubai Co. Ltd
- Pfizer Inc.
- PTC Therapeutics Inc.
- Lexicon Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- Tahio Pharmaceutical Co. Ltd
- Eli Lilly and Company
Our Clients
Related Reports
Some other reports from this category!
